Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Lionel Ades, Thomas Cluzeau, Thibault Comont, Lorea Aguinaga, Aspasia Stamatoullas, Mathieu Meunier, Emmanuel Gyan, Alice Garnier, Maud D'Aveni, Sylvain Thépot, Marie Sebert, Marius Moldovan, Anouk Walter Petrich, Karine Lemarie, Fatiha Chermat, Michaela Fontenay, Sylvie Chevret, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 351.

https://doi.org/10.1182/blood-2024-204791

Published: 2024

Journal Articles

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Blood (2024) 144 (Supplement 1): 349.

https://doi.org/10.1182/blood-2024-194510

Published: 2024

Journal Articles

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Blood (2024) 144 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2024-201317

Published: 2024

Journal Articles

A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Blood (2024) 144 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2024-198104

Published: 2024

Journal Articles

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Blood (2024) 144 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2024-200885

Published: 2024

Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux

Blood (2023) 142 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2023-185609

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Blood (2023) 142 (Supplement 1): 6471.

https://doi.org/10.1182/blood-2023-177787

Published: 2023

Journal Articles

Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study

Thomas Cluzeau, Marie Sebert, Michael Loschi, Lionel Ades, Sylvain Thepot, Martin Carre, Nicolas Duployez, Rosa Sapena, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Marie Robin

Blood (2023) 142 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2023-178021

Published: 2023

Journal Articles

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Anne Bouvier, Audrey Bidet, Pierre-Yves Dumas, Sarah Bertoli, Odile Blanchet, Sylvain Thepot, Aline Schmidt, Arnaud Pigneux, Eric Delabesse, Christian Recher, Hunault-Berger Mathilde

Blood (2023) 142 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2023-184815

Published: 2023

Journal Articles

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Ana Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose-Miguel Torregrosa-Diaz, Louis Drevon, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Maxime Jullien, Pierre Fenaux, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6469.

https://doi.org/10.1182/blood-2023-173741

Published: 2023

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Florent Malard, Sylvain Thepot, Thomas Cluzeau, Martin Carre, Delphine Lebon, Cyrielle Gasc, Juliette Jouve, Benoit Levast, Emilie Plantamura, Emmanuel Prestat, Antoine Sabourin, Joel Doré, Mohamad Mohty, Christian Recher

Blood (2022) 140 (Supplement 1): 6215–6217.

https://doi.org/10.1182/blood-2022-165938

Published: 2022

Journal Articles

Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias

Sylvain Thepot, Adja Ciss, Iden al Sabty, Jérôme Paillassa, Aline Schmidt, Aurelien Giltat, Corentin Orvain, Franck Genevieve, Marianne Schwarz, Anne Bouvier, Guillaume Mabilleau, Norbert Ifrah, Beatrice Bouvard, Mathilde Hunault

Blood (2022) 140 (Supplement 1): 9806–9807.

https://doi.org/10.1182/blood-2022-168867

Published: 2022

Journal Articles

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Blood (2022) 140 (Supplement 1): 9821–9823.

https://doi.org/10.1182/blood-2022-162278

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood (2021) 138 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2021-146846

Published: 2021

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 63.

https://doi.org/10.1182/blood-2021-147898

Published: 2021

NARROW

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only